score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Inferential		Clinical evidence	Copy Number	CCND1	Amplification				0.0	0.0		Putatively Actionable	Palbociclib	CDK4/6 inhibition	Targeted therapy	CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744								Putatively Actionable	0.0	CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506	0				CCND1 Amplification	1.0	MEL-IPI_Pat79	MEL-IPI_Pat79-Tumor-SM-53U2S	
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.P953S	0.3442	154.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137						0	0.0	0.0	0.0	RET p.P953S (Missense)		MEL-IPI_Pat79	MEL-IPI_Pat79-Tumor-SM-53U2S	MEL-IPI_Pat79-Normal-SM-4NFWB
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.6965	257.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	183.0	0.929	1.0	NRAS p.Q61K (Missense)	1.0	MEL-IPI_Pat79	MEL-IPI_Pat79-Tumor-SM-53U2S	MEL-IPI_Pat79-Normal-SM-4NFWB
Biologically Relevant				Copy Number	PMS2	Amplification				0.0	0.0																					0				PMS2 Amplification		MEL-IPI_Pat79	MEL-IPI_Pat79-Tumor-SM-53U2S	
Biologically Relevant				Copy Number	LIMK2	Amplification				0.0	0.0																					0				LIMK2 Amplification		MEL-IPI_Pat79	MEL-IPI_Pat79-Tumor-SM-53U2S	
Biologically Relevant				Copy Number	FLI1	Deletion				0.0	0.0																					0				FLI1 Deletion		MEL-IPI_Pat79	MEL-IPI_Pat79-Tumor-SM-53U2S	
Biologically Relevant				Copy Number	NTRK2	Deletion				0.0	0.0																					0				NTRK2 Deletion		MEL-IPI_Pat79	MEL-IPI_Pat79-Tumor-SM-53U2S	
Biologically Relevant				Microsatellite Stability	Supporting variants		PMS2 Amplification, PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PMS2 Amplification, PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat79		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.883																									0				COSMIC Signature (version 2) 7 (88%)		MEL-IPI_Pat79		
